Kiora Pharmaceuticals to Present Additional Data from Its ABACUS-1 Trial in Retinitis Pigmentosa at the ARVO 2024 Annual Meeting [Yahoo! Finance]
Kiora Pharmaceuticals, Inc. (KPRX)
Company Research
Source: Yahoo! Finance
additional data from the ABACUS-1 trial has been accepted for presentation at the Association for Research in Vision and Ophthalmology (ARVO) meeting in Seattle, WA, May 5-9, 2024. The additional data includes quantitative evaluation of the functional MRI measures. Qualitative assessment of fMRI demonstrated reactivation of the regions of the brain responsible for vision in a time-dependent manner, consistent with other improvements in visual function. The presentation, titled, " Synthetic phototransduction with a light-responsive molecule (KIO-301) in advanced retinitis pigmentosa: the ABACUS-1 phase I/II trial," will be presented by Professor Robert James Casson, DPhil, Head of Ophthalmology and Visual Science at Adelaide University. The ABACUS-1 study was a Phase I/II first-in-human clinical trial of the Company's molecular photoswitch, KIO-301 , in patients with late-stage retinitis pigmentosa (RP). Initial preliminary topline results from ABACUS-1 were announced at the American
Show less
Read more
Impact Snapshot
Event Time:
KPRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KPRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KPRX alerts
High impacting Kiora Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
KPRX
News
- Kiora Pharmaceuticals Receives Grant from Choroideremia Research Foundation to Fund Novel Clinical Trial Endpoints for Inherited Retinal Diseases; Approval Granted to Initiate Clinical Validation Study [Yahoo! Finance]Yahoo! Finance
- Kiora Pharmaceuticals to Present at Upcoming Investor Conferences [Yahoo! Finance]Yahoo! Finance
- Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $2.00 price target on the stock.MarketBeat
- Kiora Pharmaceuticals Reports 2023 Results; Continues to Advance Pipeline of Treatments for Rare Retinal Diseases [Yahoo! Finance]Yahoo! Finance
- Kiora Announces Publication of Phase 1 Study Demonstrating Safety, Tolerability and Anti-Inflammatory Activity of KIO-101 in the Treatment of Inflammation of the Eye [Yahoo! Finance]Yahoo! Finance
KPRX
Earnings
- 8/9/23 - Miss
KPRX
Analyst Actions
- 3/27/24 - HC Wainwright
KPRX
Sec Filings
- 3/29/24 - Form EFFECT
- 3/28/24 - Form 424B3
- 3/25/24 - Form DEF
- KPRX's page on the SEC website